Indexed keywords
DRUG DERIVATIVE;
EVEROLIMUS;
IMMUNOSUPPRESSIVE AGENT;
MTOR PROTEIN, HUMAN;
RAPAMYCIN;
TARGET OF RAPAMYCIN KINASE;
DISEASE COURSE;
DRUG ANTAGONISM;
GLOMERULUS FILTRATION RATE;
HUMAN;
KIDNEY POLYCYSTIC DISEASE;
NOTE;
NUCLEAR MAGNETIC RESONANCE IMAGING;
PATHOLOGY;
RANDOMIZED CONTROLLED TRIAL (TOPIC);
TREATMENT OUTCOME;
DISEASE PROGRESSION;
GLOMERULAR FILTRATION RATE;
HUMANS;
IMMUNOSUPPRESSIVE AGENTS;
MAGNETIC RESONANCE IMAGING;
POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT;
RANDOMIZED CONTROLLED TRIALS AS TOPIC;
SIROLIMUS;
TOR SERINE-THREONINE KINASES;
TREATMENT OUTCOME;
1
0142151493
(ed. Schrier, R. W., Lippincott Williams & Wilkins, Philadelphia
Ecder, T. et al. in Diseases of the Kidney and Urinary Tract (ed. Schrier, R. W.) 502-539 (Lippincott Williams & Wilkins, Philadelphia, 2007).
(2007)
Diseases of the Kidney and Urinary Tract , pp. 502-539
Ecder, T.1
2
34047276812
Autosomal dominant polycystic kidney disease
Torres, V. E., Harris, P C. & Pirson, Y. Autosomal dominant polycystic kidney disease. Lancet 369, 1287-1301 (2007).
(2007)
Lancet , vol.369
, pp. 1287-1301
Torres, V.E.1
Harris, P.C.2
Pirson, Y.3
3
0031459844
Mechanisms of progression in autosomal dominant polycystic kidney disease
Grantham, J. J. Mechanisms of progression in autosomal dominant polycystic kidney disease. Kidney Int. Suppl. 63, S93-S97 (1997).
(1997)
Kidney Int. Suppl , vol.63
, pp. S93-S97
Grantham, J.J.1
4
33645769011
The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease
Shillingford, J. M. et al. The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease. Proc. Natl Acad. Sci. USA 103, 5466-5471 (2006).
(2006)
Proc. Natl Acad. Sci. USA , vol.103
, pp. 5466-5471
Shillingford, J.M.1
5
34447514158
Everolimus retards cyst growth and preserves kidney function in a rodent model for polycystic kidney disease
Wu, M. et al. Everolimus retards cyst growth and preserves kidney function in a rodent model for polycystic kidney disease. Kidney Blood Press. Res. 30, 253-259 (2007).
(2007)
Kidney Blood Press. Res , vol.30
, pp. 253-259
Wu, M.1
6
40449138290
Sirolimus reduces polycystic liver volume in ADPKD patients
Qian, Q. et al. Sirolimus reduces polycystic liver volume in ADPKD patients. J. Am. Soc. Nephrol. 19, 631-638 (2008).
(2008)
J. Am. Soc. Nephrol , vol.19
, pp. 631-638
Qian, Q.1
7
77956035166
Everolimus in patients with autosomal dominant polycystic kidney disease
Walz, G. et al. Everolimus in patients with autosomal dominant polycystic kidney disease. N. Engl. J. Med. 363, 830-840 (2010).
(2010)
N. Engl. J. Med , vol.363
, pp. 830-840
Walz, G.1
8
77956029702
Sirolimus and kidney growth in autosomal dominant polycystic kidney disease
Serra, A. L. et al. Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. N. Engl. J. Med. 363, 820-829 (2010).
(2010)
N. Engl. J. Med , vol.363
, pp. 820-829
Serra, A.L.1
9
77952986486
Sirolimus therapy to halt the progression of ADPKD
Perico, N. et al. Sirolimus therapy to halt the progression of ADPKD. J. Am. Soc. Nephrol. 21, 1031-1040 (2010).
(2010)
J. Am. Soc. Nephrol , vol.21
, pp. 1031-1040
Perico, N.1
10
34548432676
Computed tomography evaluation of autosomal dominant polycystic kidney disease progression: A progress report
Antiga, L. et al. Computed tomography evaluation of autosomal dominant polycystic kidney disease progression: a progress report. Clin. J. Am. Soc. Nephrol. 1, 754-760 (2006)
(2006)
Clin. J. Am. Soc. Nephrol , vol.1
, pp. 754-760
Antiga, L.1
